Buchacher, L; Richtig, G; Dernoscheg, M; Richtig, E; Koch, L.
Permanent dose reduction due to adverse reactions does not decrease efficacy of BRAF/MEK inhibition in metastatic melanoma.
J Eur Acad Dermatol Venereol. 2023;
Doi: 10.1111/jdv.18871
Web of Science
PubMed
FullText
FullText_MUG